Biotech Exicure Secures Co-Development Deal for Burixafor with Adbiotech
XCUR sits 28% above its 52-week low of $3.101.
Summary
Exicure, a small-cap biotech firm, announced a co-development agreement with Adbiotech for its drug candidate Burixafor (Gpc-100). This partnership is a significant positive development for Exicure, especially given its recent disclosure of a critical cash position and substantial doubt about its ability to continue as a going concern. The agreement could provide crucial resources, expertise, and validation for Burixafor, potentially alleviating some of the financial pressures and advancing the drug's development. Traders will be watching for further details on the financial terms of this collaboration and its impact on the company's liquidity and pipeline progress.
At the time of this announcement, XCUR was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $3.10 to $12.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.